Jul, 04 2018 18:18 JST

Source: Eisai

Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series

An Index for Socially Responsible Investment

TOKYO, Jul, 04 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 17th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series is designed to help investors integrate environmental, social and governance (ESG) factors into their investment decisions. Of the 14 themes evaluated, Eisai received particularly high scores in "Customer Responsibility", "Corporate Governance", "Anti-Corruption", "Water Use", "Climate Change" and "Labor Standards", among others. As of June 2018, a total of 925 companies from around the world have been selected for the FTSE4Good Developed Index, including 152 companies from Japan.

Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the Dow Jones Sustainability Asia Pacific Index, another representative index for socially responsible investment, as well as the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, and the MSCI Japan ESG Select Leaders Index, which are the three ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
June 18 2019 12:32 JST
 
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
June 18 2019 12:11 JST
 
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 29 2019 09:05 JST
 
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 17 2019 15:34 JST
 
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16 2019 07:37 JST
 
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10 2019 12:34 JST
 
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 10 2019 11:55 JST
 
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 09 2019 11:33 JST
 
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 09 2019 11:06 JST
 
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
May 08 2019 08:37 JST
 
More Press release >>

Latest Press Release


More Latest Release >>